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0.90, 95% CI: 1.69 to 0.11). Six trials comparing CHM with
conventional medications demonstrated similar effect in reducing con-
stipation. One RCT showed significant positive effect of CHM plus
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Abstract: Use of Chinese herbal medicines (CHM) in symptom
management for cancer palliative care is very common in Chinese
populations but clinical evidence on their effectiveness is yet to be
synthesized.
To conduct a systematic review with meta-analysis to summarize
results from CHM randomized controlled trials (RCTs) focusing on
symptoms that are undertreated in conventional cancer palliative care.
Five international and 3 Chinese databases were searched. RCTs
evaluating CHM, either in combination with conventional treatments or
used alone, in managing cancer-related symptoms were considered
eligible. Effectiveness was quantified by using weighted mean differ-
ence (WMD) using random effect model meta-analysis.
Fourteen RCTs were included. Compared with conventional inter-
vention alone, meta-analysis showed that combined CHM and conven-
tional treatment significantly reduced pain (3 studies, pooled WMD:MD, Junkai Zhao, n, MPH,
uel Y.S. Wong, MD, and Justin C.Y. Wu, MD
chemotherapy for managing fatigue, but not in the remaining 3 RCTs.
The additional use of CHM to chemotherapy does not improve anorexia
when compared to chemotherapy alone, but the result was concluded
from 2 small trials only. Adverse events were infrequent and mild.
CHM may be considered as an add-on to conventional care in the
management of pain in cancer patients. CHM could also be considered
as an alternative to conventional care for reducing constipation. Evi-
dence on the use of CHM for treating anorexia and fatigue in cancer
patients is uncertain, warranting further research.
(Medicine 95(7):e2793)
Abbreviations: AMED = Allied and Complementary Medicine
Database, CBM = Chinese Biomedical Databases, CENTRAL =
Cochrane Central Register of Controlled Trials, CHM = Chinese
herbal medicines, CI = confidence interval, NRS = Numeric Rating
Scale, RCTs = randomized controlled trials, RR = relative risk, SR
= systematic review, WMD = weighted mean difference, XELOX =
capecitabineþ oxaliplatin.
INTRODUCTION
C ancer has been considered as a global public health issue.
1
With continuing improvement in cancer treatment, more
individuals diagnosed with cancer are surviving with the dis-
ease, indicating that a large number of patients will live with
cancer and cancer treatment-related symptoms.2,3 Symptoms
that are frequently experienced by cancer patients include
fatigue, paresthesias and dysesthesias, chronic pain, anorexia,
insomnia, limbs edema, and constipation.4 Studies have found
that among cancer patients, the prevalence was 60% to 90% for
fatigue,5 around 66% for paresthesias and dysesthesias,6 50% to
70% for chronic pain,7 around 85% for anorexia,8 30% to 50%
for insomnia,4 31% for limbs edema,6 and 30% to 80% for
constipation.9 Quality of life among cancer patients are affected
when they experience 1 or more of these symptoms.3
Despite the high prevalence of these symptoms reported in
cancer patients, treatments from conventional medicine are far
from satisfactory. Currently, treatment options for managing
fatigue are very limited. Within these few choices, adverse
effects have further restricted their clinical use,10 leaving this
symptom widely under-treated.10 For paresthesias and dys-
esthesias, although co-analgesics and antidepressants are avail-
able for controlling these symptoms, their effectiveness is not
satisfactory. A substantial number of patients are not suffi-
ciently relieved, with 10% to 15% of patients being refractory to
pharmacotherapy.11,12 For the management of cancer-relatedh Organization analgesics ladder (non-
opioids analgesics) provides a stepwise
ever, about 40% would continue to have
www.md-journal.com | 1
poorly controlled pain despite the treatment.14 Progestational
agents and corticosteroids may be effective for anorexia, but
both of them cause considerable adverse effects without
improving survival.15,16,17 For insomnia, although benzo-
diazepines and nonbenzodiazepine hypnotics are often pre-
scribed, evidence on their effectiveness among cancer
patients is lacking.18 Other study has suggested that the use
of sleeping pills may worsen symptoms severity and quality of
life among cancer patients.18 Finally, evidence on the effect of
antidepressants on improving sleep quality is mixed for cancer
patients.4
In view of these evidence gaps in conventional medicine,
the role of Chinese herbal medicine (CHM) in symptom man-
agement can be explored. There are systematic reviews (SRs)
demonstrating the effectiveness of CHM as an adjuvant treat-
ment for improving quality of life,19 increasing survival rate,20
and reducing chemotherapy-induced toxicity21 among cancer
patients. Another SR indicated mixed results for reducing
pain.22 However, there are several shortcomings with regard
to existing SRs. For instance, 1 SR did not reporting details on
treatment prescription used in control groups as well as baseline
treatment, limiting the usefulness of evidence reported.22
Another SR21 did not report the herbal compositions prescribed
in the included trials. Although results from this SR indicated
that the adjuvant use of CHM significantly reduced chemother-
apy-induced toxicity,21 clinical usefulness of such evidence is
restricted by poor reporting.
More importantly, there are no existing SRs synthesizing
evidence on the effectiveness of CHM for managing common
cancer symptoms of fatigue, paresthesias and dysesthesias,
chronic pain, anorexia, insomnia, limbs edema, and consti-
pation. In view of this research gap, this SR aims to summarize
results from CHM randomized controlled trials (RCTs) focus-
ing on these outcomes.
METHODS
This systematic review and meta-analysis was strictly
reported according to the PRISMA checklist. Ethical approval
was not necessary for this study because all the analyses were






We included studies according to the following criteria:
RCTs comparing effect of CHM, either in combination with1.
other treatments or used alone, in managing cancer or
cancer treatment-related symptoms. There is no restriction
of the type of cancer diagnosis.
The RCT has to report the effectiveness of CHM on at least
1 of the following outcomes measured with validated
instruments: fatigue, paresthesias and dysesthesias, chronic
pain, anorexia, insomnia, limbs edema, and constipation.
For measurement of pain, 3 validated scales (Visual
Analogue Scales, Numerical Rating Scales, and Verbal
Rating Scales) recommended by the Research Network of
the European Association of Palliative Care23 should
be used.
The RCT included at least 1 CHM indexed in the 2010
China Pharmacopeia Chinese herbal medicine index.24 We
did not impose any restriction on the forms of CHM, with
single herbs, herbal formulations, and Chinese proprietary
medicines included.
Control group included conventional treatment, chemother-





RCT reported detailed information on the regimens
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prescribed in both treatment and control groups. Follow-
up duration should also be clearly reported where
applicable.
Literature Search
Five international databases and 3 Chinese databases were
searched without any language restriction. International data-
bases included the Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE, EMBASE, CINAHL Plus, the
Allied and Complementary Medicine Database (AMED). When
searching MEDLINE25 and EMBASE,26 specialized search
filter for clinical trials were used. Chinese databases include
Chinese Biomedical Databases, Wan Fang Digital Journals, and
Taiwan Periodical Literature Databases. Detailed search strat-
egies and related results were shown in Appendix 1, http://
links.lww.com/MD/A692.
Literature Selection, Data Extraction, and Risk of
Bias Assessment
Eligibility of the retrieved studies were screened and
assessed according to inclusion criteria. The following data
were extracted from included RCTs: 1) Basic characteristics of
the RCT, name of first author, year of publication, country
where the trial was conducted, eligibility criteria for partici-
pants, diagnostic criteria of 2) Information related to patients’
characteristics, CHM, control interventions, and outcomes. 3)
Effect size for each interested outcome and adverse effects
related to CHM treatment.
The Cochrane risk of bias tool27 was used to assess risk of
bias of included RCTs. Risk of bias in 6 domains were assessed
for each included RCT, including sequence generation, allo-
cation concealment, blinding of participants and personnel,
blinding of outcome assessments, incomplete outcome data,
and selective reporting. Based on the information provided by
the trial authors, each domain was judged to have low, high, or
unclear risk of bias.
Two reviewers independently selected the literature (JZ,
MF), extracted the data, and assessed the risk of bias of included
studies (XW, PL), with disagreement resolved by discussion and
consensus. A third reviewer (VC) was consulted if disagreement
cannot be resolved between the two reviewers.
Data Analysis
Relative risk (RR) and 95% confidence interval (CI) was
used to express effectiveness of CHM when the outcome was
dichotomous. Weighted mean difference and 95% CI was used
when the outcome was continuous. Level of heterogeneity
across trials was measured with I2 statistic, with I2< 25%
considered as low level of heterogeneity, 25% to 50% as
moderate level, and higher than 50% as high level.28 Random
effects model was used to account for variations across trials29
during data synthesis.
Publication bias would be assessed using funnel plot if more
than 10 trials were available for a single outcome.30 The symmetry
of the funnel plot would be assessed with Egger test, with a P< 0.1
indicating presence of publication bias. Data analyses were con-
ducted with STATA Version 13.0 (STATA Corporation, College
Station, TX), with a 2-tailed significance level of 0.05 except forfor publication bias (P¼ 0.10). The protocol of this SR has
n registered in PROSPERO (http://www.crd.york.ac.uk/
SPERO/DisplayPDF.php?ID=CRD42015023931).
opyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 1. Flow chart for literature selection of randomized controlled trial on Chinese herbal medicine for symptoms management in
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Study Selection
Electronic databases search yielded 4767 records, of which
797 duplications were excluded, and 3970 records remained for
citation screening. Three thousand seven hundred eighteen
citations were excluded after the screening of titles and
abstracts, and 252 full texts were retrieved for eligibility
assessment. Among them, 238 publications were excluded
because of the following reasons: CHM was used in the control
group (n¼ 26); did not report prespecified outcomes (n¼ 34);
did not use a validated instrument for outcome assessment
(n¼ 111); no control group in the study (n¼ 25); did not include
cancer patients (n¼ 3); did not evaluate CHM (n¼ 24); time
points for outcome measurement were unspecified (n¼ 12); did
cancer palliative care.not report details on the control interventions (n¼ 1), not an
RCT (n¼ 1), and did not report number of patients in each
group (n¼ 1). As a result, 14 RCTs were included in this SR.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.Detailed flow chart for literature selection can be found in
Figure 1.
Characteristics of Included Studies
The 14 RCTs were published between 2006 and 2013, and
all were conducted in mainland China. Majority of the included
RCTs did not have any restrictions on the site of tumors (n¼ 8).
Three only included colorectal cancer patients, the remaining 3
focused on patients with hematological malignancies, lung
cancer, and breast cancer respectively. Forms of CHM included
oral medications, external applications, and clyster. Details of
each CHM prescription were shown in Appendix 2, http://
links.lww.com/MD/A692.
Six RCTs31–36 assessed the effectiveness of CHM for
constipation by directly comparing it with conventional medi-
cine; 7 RCTs investigated the add-on effects of CHM on top of
conventional medicine or chemotherapy for managing fati-
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Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.patients; the remaining RCT44 compared the combination of
Gui-dan-san-zi-san, hyperthermia and radiotherapy with radio-
therapy alone in reducing pain among cancer patients. Treat-
ment durations range from 7 to 60 days, with the majority of
them assessed outcome immediately after completion of CHM
treatment, with only 2 RCTs35,44 followed up the patients after
the treatment ended. Details were seen in Table 1.
Risk of Bias of Included RCTs
All the included RCTs were published in Chinese and
provided limited information regarding risk of bias. Although
all RCTs stated that patients were randomly allocated to treat-
ment and control groups, only 4 of them described how the
random sequences were generated and were judged to have low
risk of bias for sequence generation. One of the 14 RCTs
mentioned the use of sequentially numbered, opaque, and sealed
envelope for allocation concealment and hence judged to have
low risk of bias. The remaining 13 were judged to have unclear
risk of bias as no information about allocation concealment
were provided. Thirteen and 8 RCTs were judged to have high
risk of bias for blinding of participants and personnel, and
blinding of outcome assessments, respectively. The remaining 1
and 4 RCTs were judged to have unclear risk of bias for blinding
of participants and personnel, and blinding of outcome assess-
ments, respectively. On the other hand, all the included RCTs
had low risk of bias for incomplete outcome data and selective
reporting for our interested outcomes. Details are presented in
Table 2.
Effectiveness of CHM for Symptom Management
for Cancer Palliative Care
Pain
Three RCTs reported results on pain relief (Figure 2).
Changes in pain severity were measured with Numeric Rating
Scale in these 3 studies. One RCT42 only included advance
colorectal cancer patients while the remaining 2 RCTs41,44
included patients with various types of advanced cancer.
Meta-analysis of these trials showed that, combined CHM
and conventional treatment significantly reduced pain score
as compared with conventional medicine alone (pooled
WMD:0.90, 95% CI: 1.69 to 0.11, I2¼ 87.7%). Signifi-
cant heterogeneity was observed, which may account for by the
differences in CHM formulae, treatment duration, cancer types,
and baseline treatment. Subgroup analysis was not conducted
because of the limited number of studies. Sensitivity analysis
based on rigor was not conducted as all the 3 RCTs were judged
to have unclear risk of bias for sequence generation.
One41 of the 3 RCTs reported adverse events. As compared
to fentanyl transdermal patch alone, patients who used
additional Jia-wei-xiang-sha-liu-jun-zi decoction had similar
occurrence in vomiting, dizziness, drowsiness, abdominal dis-
comfort, and skin allergy.
Constipation
Seven RCTs investigated the effect of CHM in managing
constipation (Table 3). One RCT40 compared Tong-Tai decoc-
tion plus chemotherapy to chemotherapy alone. No difference
was found in terms of the proportion of patient achieving
satisfactory relief between the 2 groups. The remaining 6
Chinese Herbal Medicine for Cancer Palliative CareRCTs31–36 compared CHM to conventional medications in
managing constipation. Results showed that CHM and conven-
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Medicine  Volume 95, Number 7, February 2016 Chinese Herbal Medicine for Cancer Palliative CareData were not pooled because of the differences in the definition
of satisfactory relief among included studies.
Three of the 7 RCTs mentioned adverse events. Two31,33
of them reported no adverse events in both treatment and control
groups except for mild abdominal discomfort. No additional
treatment was required to manage this event. The remaining
one40 reported that no significant difference between Tong-tai
decoction plus XELOX (capecitabine þ oxaliplatin) and
XELOX alone group with respect to the incidence of che-
motherapy-induced toxicity among colorectal cancer patients.
Fatigue
Four RCTs reported reduction of fatigue (Table 3). Three
RCTs38–40 reported no significant difference between com-
bined use of CHM and chemotherapy versus chemotherapy
alone for reducing fatigue. The remaining RCT37 compared the
combination of chemotherapy (Epirubicin plus Taxol) and Fu-
zheng decoction to chemotherapy alone in breast cancer
patients. After 9 weeks of treatment, the combined treatment
group showed significantly lower Fatigue Symptom Inventory
score than the chemotherapy alone group (MD: 18.62, 95%
CI: 24.08 to 13.16). Because of the heterogeneity in out-
come measurement approach, data were not pooled among
included RCTs.
Three of the 4 RCTs provided information on adverse
effect. Two studies37,39 reported that the CHM and chemother-
apy-combined treatment group had significantly lower inci-
dence in chemotherapy-induced toxicity including leucopenia,
neurotoxicity, and nausea and vomiting. One38 reported that
there was no adverse event observed.
Anorexia
Two RCTs reported evidence on CHM for treating anor-
FIGURE 2. Meta-analysis on the additional use of Chinese herba
Chinese herbal medicineþ chemotherapy vs chemotherapy aloneexia in cancer patients (Table 3). One43 compared Qi-ge-kai-
wei decoction plus megestrol acetate versus megestrol acetate
alone in advanced lung cancer patients. Although a higher
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.proportion of patients in the combined treatment group reported
improvement (93.8% versus 87.5%), the difference was not of
statistical significance. The other RCT40 found that the com-
bined use of Tong-tai decoction and chemotherapy showed
more improvement than chemotherapy alone in advanced color-
ectal cancer patients (55.0% versus 45.0%), but again no
significant difference was found. Considering the clinical
heterogeneity of these 2 studies, and different criteria
used for defining satisfactory relief, meta-analysis was not
conducted.
One study43 reported adverse effects. Although the CHM
and conventional medicine combined treatment group showed
fewer incidence in alanine aminotransferase increment, for
thrombotic vasculitis, edema, high blood pressure or blood
glucose, constipation, heart failure, and difficulty in breathing,
the difference was not significant.
DISCUSSION
This SR summarized evidence on the effectiveness of
CHM for the management of pain, constipation, fatigue, and
anorexia among cancer patients. Fourteen RCTs with a total of
878 cancer patients were included in this SR. Our results
showed that the combined use of CHM and conventional
medicine slightly relieved pain when compared with conven-
tional treatment alone. CHM alone showed similar effectiveness
with conventional medicine in managing constipation. The
additional use of Fu-zheng decoction can reduce fatigue in
breast cancer patients who are receiving chemotherapy. Current
evidence did not show any superior effect on combined use of
CHM and conventional medicine for anorexia when compared
to conventional medicine alone. On safety, patients in the
combined group generally showed lower or similar occurrence
of adverse events when compared with patients in conventional
edicine for reducing pain score in cancer patients (Comparison:medicine only group. We did not identify any eligible RCT
providing evidence on CHM for managing paresthesias and
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The role of CHM in symptom management of cancer
patients has gained increasing attention. Based on previous
SRs, no firm conclusion has been reached on using CHM for
the managing pain45,46 and fatigue,45 because of the lack of
‘‘rigorous clinical trials.’’ In current SR, we only included
RCTs which reported detailed methodological details. Results
from our study suggested that clinicians may consider
additional use of CHM on top of conventional care for better
management of pain and fatigue, of which both are under-
treated in clinical practice.47,48 CHM could be considered as an
alternative choice for treating constipation in cancer patients as
it has similar effectiveness as conventional medicine.
All included RCTs generally had short treatment duration,
with 2 of them shortly followed up the patients (14–28 days)
after treatment. That raises the question of whether treatment
and follow-up durations were long enough for CHM to demon-
strate its beneficial effects.22 Future RCTs on this area should
consider appropriate treatment and follow-up duration based on
expert consensus.
All the included RCTs were published in Chinese and we
have observed a lack of compliance to the Chinese version
COSORT statement.49 Poor reporting is the major contributor to
uncertainties in our risk of bias assessment. For example,
although all the studies stated themselves as RCTs, more than
half of them (10/14) did not provide information on how random
sequences were generated. Also, only 1 RCT mentioned about
allocation concealment. Blinding is another key limitation to the
evidence base as all the included outcomes were measured in a
subjective manner.50 As a result, we cannot exclude the possib-
ility of overestimating or underestimating the effectiveness of
CHM.51 That said, all included studies had good performance in
preventing bias related to incomplete outcome data and selec-
tive outcome reporting.
Among RCTs that reported adverse event outcomes,
results were consistent with other reviews,22,45 which indicated
that CHM is generally safe with low risk of incurring serious
adverse effect. However, safety issue did not receive attention in
6 of the 14 RCTs, which indicates the need of paying more
attention on safety surveillance in future trials.22
During literature selection, more than 100 RCTs were
excluded due to not using validated instrument in outcome
assessment. This phenomenon is consistent with findings from
other researchers.22 Self-developed outcome assessment criteria
were often used in these studies without prior validation, and
some of them did not even provide information on the criteria
they used. That could be considered as a huge waste of research
resources as results from these studies cannot generate any
useable or meaningful clinical evidence. Future RCTs are
strongly suggested to use internationally recognized and vali-
dated scales to measure outcomes, so as to facilitate the
comparison with similar studies, and enhance usefulness of
the research findings.
Readers should be noted that all the included RCTs were
conducted in Chinese population under Chinese health care
settings, which may limit the generalizability of results.
Because of the limited number of included studies, we did
not assess the publication bias in this SR, so we cannot
determine whether such bias exist or not.
In conclusion, CHM may be considered as an add-on to
conventional medicine in the management of pain in cancer
patients. CHM could also be considered as an alternative to
Medicine  Volume 95, Number 7, February 2016conventional medicine for reducing constipation. Evidence on
the use of CHM for treating anorexia and fatigue in cancer
patients is uncertain, warranting further research. Future RCTs
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.should improve in the following areas: 1) choosing an inter-
nationally recognized and validated instruments for outcome
measurement; 2) reporting detailed safety outcomes; and 3)
implementing strict adherence to the CONSORT reporting
statements.49,52
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